This is a StreetInsider.com Premium Only Page

OptiNose (OPTN) –

Apr 25, 2024 07:42 AM Form 8-K OptiNose, Inc. For: Apr 25

Apr 25, 2024 07:01 AM OptiNose (OPTN) Provides Corporate Update on XHANCE Launch

Apr 25, 2024 07:00 AM Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

Apr 4, 2024 04:01 PM Optinose to Present at the Needham Virtual Healthcare Conference

Mar 19, 2024 12:46 PM Form 4 OptiNose, Inc. For: Mar 18 Filed by: Krick Anthony J

Mar 19, 2024 12:45 PM Form 4 OptiNose, Inc. For: Mar 15 Filed by: Marino Michael F III

Mar 19, 2024 12:44 PM Form 4 OptiNose, Inc. For: Mar 15 Filed by: Mahmoud Ramy A

Mar 18, 2024 08:40 AM Optinose (OPTN) PT Raised to $4 at Lake Street Capital Markets

Mar 15, 2024 03:37 PM Form 8-K OptiNose, Inc. For: Mar 15

Mar 15, 2024 03:35 PM OptiNose (OPTN) Announces XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Mar 15, 2024 03:34 PM XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Mar 15, 2024 03:26 PM OptiNose (OPTN) Halted, News Pending

Mar 14, 2024 04:27 PM Form 8-K OptiNose, Inc. For: Mar 09

Mar 11, 2024 08:52 AM H.C. Wainwright Starts Optinose (OPTN) at Buy

Mar 8, 2024 04:10 PM Form 8-K OptiNose, Inc. For: Mar 08

Mar 7, 2024 04:33 PM Form S-8 OptiNose, Inc.

Mar 7, 2024 07:04 AM OptiNose (OPTN) Reports In-Line Q4 EPS, provides guidance

Mar 7, 2024 07:02 AM Form 10-K OptiNose, Inc. For: Dec 31

Mar 7, 2024 07:01 AM Form 8-K OptiNose, Inc. For: Mar 07

Mar 7, 2024 07:00 AM Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Feb 29, 2024 04:40 PM Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Feb 29, 2024 04:07 PM Form 4 OptiNose, Inc. For: Feb 28 Filed by: Spence Paul Jr.

Feb 29, 2024 04:07 PM Form 4 OptiNose, Inc. For: Feb 28 Filed by: Krick Anthony J

Feb 29, 2024 04:06 PM Form 4 OptiNose, Inc. For: Feb 28 Filed by: Marino Michael F III

Feb 29, 2024 04:05 PM Form 4 OptiNose, Inc. For: Feb 28 Filed by: Mahmoud Ramy A

Feb 23, 2024 07:09 AM Form 8-K OptiNose, Inc. For: Feb 19

Feb 22, 2024 04:28 PM Form SC 13G/A OptiNose, Inc. Filed by: Rosalind Advisors, Inc.

Feb 14, 2024 08:49 PM Form SC 13G/A OptiNose, Inc. Filed by: Rosalind Advisors, Inc.

Feb 14, 2024 04:39 PM Form SC 13G/A OptiNose, Inc. Filed by: GREAT POINT PARTNERS LLC

Feb 13, 2024 05:23 PM Form SC 13G/A OptiNose, Inc. Filed by: ACORN BIOVENTURES, L.P.

Feb 9, 2024 09:30 AM Form SC 13G/A OptiNose, Inc. Filed by: FMR LLC

Feb 7, 2024 04:16 PM Form SC 13G/A OptiNose, Inc. Filed by: KRUTTSCHNITT THEODORE H III

Feb 1, 2024 02:44 PM Form 4 OptiNose, Inc. For: Jan 31 Filed by: Mahmoud Ramy A

Jan 30, 2024 04:06 PM Form SC 13G/A OptiNose, Inc. Filed by: Avista Capital Partners II GP, LLC

Jan 18, 2024 12:00 PM Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

Dec 21, 2023 04:12 PM Form 8-K OptiNose, Inc. For: Dec 18

Dec 20, 2023 12:22 PM Form 4 OptiNose, Inc. For: Dec 15 Filed by: Mahmoud Ramy A

Dec 20, 2023 12:20 PM Form 4 OptiNose, Inc. For: Dec 15 Filed by: Marino Michael F III

Dec 6, 2023 07:02 AM OptiNose (OPTN) Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

Dec 6, 2023 07:02 AM Form 8-K OptiNose, Inc. For: Dec 06

Dec 6, 2023 07:00 AM Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

Nov 22, 2023 09:00 AM Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 9, 2023 07:07 AM OptiNose (OPTN) Tops Q3 EPS by 1c

Nov 9, 2023 07:04 AM Form 10-Q OptiNose, Inc. For: Sep 30

Nov 9, 2023 07:02 AM Form 8-K OptiNose, Inc. For: Nov 09

Nov 9, 2023 07:00 AM Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Oct 27, 2023 08:00 AM Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

Sep 22, 2023 09:01 AM Optinose to Present at the 2023 Cantor Global Healthcare Conference

Sep 19, 2023 07:06 PM Form 4 OptiNose, Inc. For: Sep 15 Filed by: Mahmoud Ramy A

Sep 19, 2023 07:05 PM Form 4 OptiNose, Inc. For: Sep 15 Filed by: Marino Michael F III